Symbols / MRNA $53.31 +1.43%
MRNA Chart
About
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 21.05B |
| Enterprise Value | 16.56B | Income | -2.82B | Sales | 1.94B |
| Book/sh | 21.95 | Cash/sh | 14.68 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4700 | IPO | — |
| P/E | — | Forward P/E | -11.68 | PEG | — |
| P/S | 10.83 | P/B | 2.43 | P/C | — |
| EV/EBITDA | -5.79 | EV/Sales | 8.52 | Quick Ratio | 3.06 |
| Current Ratio | 3.29 | Debt/Eq | 15.09 | LT Debt/Eq | — |
| EPS (ttm) | -7.26 | EPS next Y | -4.56 | EPS Growth | — |
| Revenue Growth | -29.80% | Earnings | 2026-04-30 | ROA | -14.51% |
| ROE | -28.87% | ROIC | — | Gross Margin | -105.76% |
| Oper. Margin | -126.40% | Profit Margin | -145.16% | Shs Outstand | 394.94M |
| Shs Float | 368.32M | Short Float | 21.57% | Short Ratio | 6.63 |
| Short Interest | — | 52W High | 59.55 | 52W Low | 22.28 |
| Beta | 1.35 | Avg Volume | 11.94M | Volume | 6.96M |
| Target Price | $42.90 | Recom | Hold | Prev Close | $52.56 |
| Price | $53.31 | Change | 1.43% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$42.90
Mean price target
2. Current target
$53.31
Latest analyst target
3. DCF / Fair value
$-60.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$53.31
Low
$12.00
High
$135.00
Mean
$42.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | Piper Sandler | Overweight → Overweight | $69 |
| 2026-02-17 | main | Goldman Sachs | Neutral → Neutral | $41 |
| 2026-02-17 | main | RBC Capital | Sector Perform → Sector Perform | $30 |
| 2026-02-17 | main | Evercore ISI Group | In-Line → In-Line | $35 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $28 |
| 2025-12-12 | init | Jefferies | — → Hold | $30 |
| 2025-11-21 | reit | Piper Sandler | Overweight → Overweight | $63 |
| 2025-11-21 | main | RBC Capital | Sector Perform → Sector Perform | $25 |
| 2025-11-21 | main | Leerink Partners | Underperform → Underperform | $18 |
| 2025-11-10 | main | B of A Securities | Underperform → Underperform | $21 |
| 2025-11-07 | main | Barclays | Equal-Weight → Equal-Weight | $25 |
| 2025-10-23 | main | UBS | Buy → Buy | $40 |
| 2025-10-23 | main | JP Morgan | Underweight → Underweight | $25 |
| 2025-10-23 | main | Citigroup | Neutral → Neutral | $28 |
| 2025-10-20 | reit | Needham | Hold → Hold | — |
| 2025-10-10 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $32 |
| 2025-08-22 | main | Leerink Partners | Underperform → Underperform | $15 |
| 2025-08-04 | main | Barclays | Equal-Weight → Equal-Weight | $31 |
| 2025-07-22 | main | B of A Securities | Underperform → Underperform | $25 |
| 2025-05-22 | main | JP Morgan | Underweight → Underweight | $26 |
- Moderna to pay $950M to end vaccine patent battle, avoid royalties - Stock Titan ue, 03 Mar 2026 08
- Moderna Pops As Vinay Prasad, The FDA's Controversial Vaccine Head, Will Depart In April - Investor's Business Daily Fri, 06 Mar 2026 08
- The S&P 500's 3 Best-Performing Stocks so far in 2026 - MarketBeat Mon, 16 Mar 2026 12
- MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Yahoo Finance Wed, 04 Mar 2026 08
- MRNA Stock: Why 16% Pop May Signal More Upside - Forbes hu, 22 Jan 2026 08
- Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure - Quiver Quantitative Sat, 07 Mar 2026 17
- Why Moderna (MRNA) Stock Is Trading Up Today - Finviz Wed, 04 Mar 2026 08
- MRNA Stock Surges 34% With A 10-day Winning Spree On Earnings Beat And FDA Nod - Trefis Sat, 28 Feb 2026 08
- Moderna (MRNA) Declines More Than Market: Some Information for Investors - Yahoo Finance Fri, 13 Mar 2026 21
- $MRNA stock is up 2% today. Here's what we see in our data. - Quiver Quantitative Mon, 09 Mar 2026 19
- MRNA Stock Surges 28% In 8-day Spree On FDA Reversal, Analyst Upgrades - Trefis hu, 26 Feb 2026 08
- 3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Yahoo Finance Wed, 25 Feb 2026 08
- MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Yahoo Finance Mon, 02 Mar 2026 08
- Why Is Moderna (MRNA) Stock Rocketing Higher Today - Yahoo Finance Fri, 19 Dec 2025 08
- Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Mon, 26 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11797 | — | — | KLINGER SHANNON THYME | Officer | — | 2026-03-05 00:00:00 | D | nan |
| 1 | 11797 | — | — | MOCK JAMES M | Chief Financial Officer | — | 2026-03-05 00:00:00 | D | nan |
| 2 | 23884 | — | Conversion of Exercise of derivative security at price 30.96 per share. | KLINGER SHANNON THYME | Officer | — | 2026-03-02 00:00:00 | D | 429880.0 |
| 3 | 13885 | — | Sale at price 52.29 per share. | KLINGER SHANNON THYME | Officer | — | 2026-03-02 00:00:00 | D | 726047.0 |
| 4 | 39830 | — | — | HOGE STEPHEN | President | — | 2026-02-27 00:00:00 | D | nan |
| 5 | 11004 | — | — | MOCK JAMES M | Chief Financial Officer | — | 2026-02-27 00:00:00 | D | nan |
| 6 | 160009 | — | Conversion of Exercise of derivative security at price 19.15 per share. | HOGE STEPHEN | President | — | 2026-02-23 00:00:00 | D | 3064172.0 |
| 7 | 160009 | — | Sale at price 48.84 per share. | HOGE STEPHEN | President | — | 2026-02-23 00:00:00 | D | 7814840.0 |
| 8 | 11271 | — | Stock Award(Grant) at price 0.00 per share. | BANCEL STEPHANE J | Chief Executive Officer | — | 2026-02-11 00:00:00 | D | — |
| 9 | 2630 | — | Stock Award(Grant) at price 0.00 per share. | MOCK JAMES M | Chief Financial Officer | — | 2026-02-11 00:00:00 | D | — |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.05M | -714.17K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.01 | 0.21 | 0.13 |
| NormalizedEBITDA | -2.54B | -3.34B | -3.62B | 9.77B |
| TotalUnusualItems | -5.00M | -56.00M | -72.00M | -20.00M |
| TotalUnusualItemsExcludingGoodwill | -5.00M | -56.00M | -72.00M | -20.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.82B | -3.56B | -4.71B | 8.36B |
| ReconciledDepreciation | 215.00M | 189.00M | 621.00M | 348.00M |
| ReconciledCostOfRevenue | 868.00M | 1.46B | 4.69B | 5.42B |
| EBITDA | -2.54B | -3.39B | -3.62B | 9.77B |
| EBIT | -2.76B | -3.58B | -4.24B | 9.42B |
| NetInterestIncome | 304.00M | 401.00M | 421.00M | 200.00M |
| InterestExpense | 10.00M | 24.00M | 38.00M | 29.00M |
| InterestIncome | 314.00M | 425.00M | 421.00M | 200.00M |
| NormalizedIncome | -2.82B | -3.51B | -4.71B | 8.36B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.82B | -3.56B | -4.71B | 8.36B |
| TotalExpenses | 5.00B | 7.14B | 10.99B | 9.46B |
| TotalOperatingIncomeAsReported | -3.07B | -3.94B | -4.24B | 9.42B |
| DilutedAverageShares | 384.00M | 382.00M | 416.00M | 431.00M |
| BasicAverageShares | 384.00M | 382.00M | 394.00M | 403.00M |
| DilutedEPS | -9.28 | -12.33 | 20.12 | 28.29 |
| BasicEPS | -9.28 | -12.33 | 21.26 | 30.31 |
| DilutedNIAvailtoComStockholders | -2.82B | -3.56B | -4.71B | 8.36B |
| NetIncomeCommonStockholders | -2.82B | -3.56B | -4.71B | 8.36B |
| NetIncome | -2.82B | -3.56B | -4.71B | 8.36B |
| NetIncomeIncludingNoncontrollingInterests | -2.82B | -3.56B | -4.71B | 8.36B |
| NetIncomeContinuousOperations | -2.82B | -3.56B | -4.71B | 8.36B |
| TaxProvision | 54.00M | -46.00M | 772.00M | 1.21B |
| PretaxIncome | -2.77B | -3.61B | -3.94B | 9.57B |
| OtherIncomeExpense | 2.00M | -63.00M | -124.00M | -45.00M |
| OtherNonOperatingIncomeExpenses | 7.00M | -7.00M | -124.00M | -45.00M |
| GainOnSaleOfSecurity | -5.00M | -56.00M | -72.00M | -20.00M |
| NetNonOperatingInterestIncomeExpense | 304.00M | 401.00M | 421.00M | 200.00M |
| InterestExpenseNonOperating | 10.00M | 24.00M | 38.00M | 29.00M |
| InterestIncomeNonOperating | 314.00M | 425.00M | 421.00M | 200.00M |
| OperatingIncome | -3.07B | -3.94B | -4.24B | 9.42B |
| OperatingExpense | 4.13B | 5.68B | 6.30B | 4.04B |
| OtherOperatingExpenses | -22.00M | -37.00M | -94.00M | -388.00M |
| ResearchAndDevelopment | 3.13B | 4.54B | 4.84B | 3.29B |
| SellingGeneralAndAdministration | 1.02B | 1.17B | 1.55B | 1.13B |
| GrossProfit | 1.05B | 1.74B | 2.06B | 13.46B |
| CostOfRevenue | 868.00M | 1.46B | 4.69B | 5.42B |
| TotalRevenue | 1.92B | 3.20B | 6.75B | 18.88B |
| OperatingRevenue | 3.30B | 4.52B | 8.20B | 18.43B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 394.00M | 386.00M | 382.00M | 385.00M |
| ShareIssued | 394.00M | 386.00M | 382.00M | 385.00M |
| TotalDebt | 1.30B | 747.00M | 1.24B | 1.20B |
| TangibleBookValue | 8.55B | 10.81B | 13.76B | 19.12B |
| InvestedCapital | 9.24B | 10.90B | 13.85B | 19.12B |
| WorkingCapital | 4.56B | 5.89B | 7.31B | 8.51B |
| NetTangibleAssets | 8.55B | 10.81B | 13.76B | 19.12B |
| CapitalLeaseObligations | 715.00M | 747.00M | 1.24B | 1.20B |
| CommonStockEquity | 8.65B | 10.90B | 13.85B | 19.12B |
| TotalCapitalization | 9.24B | 10.90B | 13.85B | 19.12B |
| TotalEquityGrossMinorityInterest | 8.65B | 10.90B | 13.85B | 19.12B |
| StockholdersEquity | 8.65B | 10.90B | 13.85B | 19.12B |
| GainsLossesNotAffectingRetainedEarnings | 45.00M | -10.00M | -123.00M | -370.00M |
| OtherEquityAdjustments | 45.00M | -10.00M | -123.00M | -370.00M |
| RetainedEarnings | 7.22B | 10.04B | 13.61B | 18.32B |
| AdditionalPaidInCapital | 1.38B | 866.00M | 371.00M | 1.17B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.69B | 3.24B | 4.57B | 6.74B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.70B | 1.03B | 1.56B | 1.81B |
| OtherNonCurrentLiabilities | 36.00M | 36.00M | 21.00M | 135.00M |
| TradeandOtherPayablesNonCurrent | 249.00M | 231.00M | 235.00M | |
| NonCurrentDeferredLiabilities | 153.00M | 58.00M | 83.00M | 673.00M |
| NonCurrentDeferredRevenue | 153.00M | 58.00M | 83.00M | 673.00M |
| LongTermDebtAndCapitalLeaseObligation | 1.26B | 710.00M | 1.22B | 1.00B |
| LongTermCapitalLeaseObligation | 673.00M | 710.00M | 1.22B | 1.00B |
| LongTermDebt | 590.00M | |||
| CurrentLiabilities | 1.99B | 2.21B | 3.02B | 4.92B |
| OtherCurrentLiabilities | 143.00M | 184.00M | 41.00M | 53.00M |
| CurrentDeferredLiabilities | 99.00M | 153.00M | 568.00M | 2.04B |
| CurrentDeferredRevenue | 99.00M | 153.00M | 568.00M | 2.04B |
| CurrentDebtAndCapitalLeaseObligation | 42.00M | 37.00M | 25.00M | 196.00M |
| CurrentCapitalLeaseObligation | 42.00M | 37.00M | 25.00M | 196.00M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 420.00M | 312.00M | 245.00M | 190.00M |
| CurrentProvisions | 509.00M | 370.00M | 556.00M | |
| PayablesAndAccruedExpenses | 774.00M | 1.15B | 1.58B | 2.45B |
| CurrentAccruedExpenses | 457.00M | 745.00M | 997.00M | 1.91B |
| Payables | 317.00M | 405.00M | 583.00M | 535.00M |
| TotalTaxPayable | 3.00M | 63.00M | 48.00M | 876.00M |
| IncomeTaxPayable | 3.00M | 63.00M | 48.00M | 876.00M |
| AccountsPayable | 317.00M | 405.00M | 520.00M | 487.00M |
| TotalAssets | 12.34B | 14.14B | 18.43B | 25.86B |
| TotalNonCurrentAssets | 5.79B | 6.04B | 8.10B | 12.43B |
| OtherNonCurrentAssets | 160.00M | 171.00M | 181.00M | 946.00M |
| NonCurrentPrepaidAssets | 100.00M | 139.00M | 342.00M | 0.00 |
| NonCurrentDeferredAssets | 81.00M | 81.00M | 81.00M | 982.00M |
| NonCurrentDeferredTaxesAssets | 81.00M | 81.00M | 81.00M | 982.00M |
| NonCurrentAccountsReceivable | 161.00M | 97.00M | ||
| InvestmentsAndAdvances | 2.34B | 2.51B | 4.74B | 8.36B |
| InvestmentinFinancialAssets | 2.34B | 2.49B | 4.68B | 8.32B |
| AvailableForSaleSecurities | 2.34B | 2.49B | 4.68B | 8.32B |
| LongTermEquityInvestment | 6.00M | 14.00M | 66.00M | 42.00M |
| GoodwillAndOtherIntangibleAssets | 97.00M | 92.00M | 96.00M | 0.00 |
| OtherIntangibleAssets | 45.00M | 40.00M | 44.00M | |
| Goodwill | 52.00M | 52.00M | 52.00M | 0.00 |
| NetPPE | 2.85B | 2.96B | 2.66B | 2.14B |
| AccumulatedDepreciation | -737.00M | -527.00M | -433.00M | -658.00M |
| GrossPPE | 3.59B | 3.48B | 3.09B | 2.80B |
| Leases | 403.00M | 207.00M | 522.00M | 460.00M |
| ConstructionInProgress | 298.00M | 1.06B | 860.00M | 281.00M |
| OtherProperties | 1.39B | 1.24B | 1.59B | 1.99B |
| MachineryFurnitureEquipment | 235.00M | 181.00M | 100.00M | 59.00M |
| BuildingsAndImprovements | 1.18B | 743.00M | 0.00 | |
| LandAndImprovements | 78.00M | 59.00M | 22.00M | 11.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 6.54B | 8.10B | 10.32B | 13.43B |
| OtherCurrentAssets | 45.00M | 58.00M | 88.00M | 44.00M |
| HedgingAssetsCurrent | 21.00M | |||
| PrepaidAssets | 263.00M | 307.00M | 350.00M | 851.00M |
| Inventory | 153.00M | 117.00M | 202.00M | 949.00M |
| FinishedGoods | 33.00M | 28.00M | 24.00M | 169.00M |
| WorkInProcess | 29.00M | 26.00M | 15.00M | 205.00M |
| RawMaterials | 91.00M | 63.00M | 163.00M | 575.00M |
| Receivables | 284.00M | 592.00M | 1.08B | 1.69B |
| OtherReceivables | 13.00M | 58.00M | 61.00M | 53.00M |
| TaxesReceivable | 45.00M | 117.00M | 69.00M | 150.00M |
| AccruedInterestReceivable | 42.00M | 59.00M | 59.00M | 61.00M |
| NotesReceivable | 0.00 | 36.00M | 0.00 | |
| AccountsReceivable | 184.00M | 358.00M | 892.00M | 1.39B |
| AllowanceForDoubtfulAccountsReceivable | -184.00M | -340.00M | -692.00M | 0.00 |
| GrossAccountsReceivable | 368.00M | 698.00M | 1.58B | 1.39B |
| CashCashEquivalentsAndShortTermInvestments | 5.80B | 7.03B | 8.60B | 9.90B |
| OtherShortTermInvestments | 3.20B | 5.10B | 5.70B | 6.70B |
| CashAndCashEquivalents | 2.60B | 1.93B | 2.91B | 3.21B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.08B | -4.05B | -3.83B | 4.58B |
| RepurchaseOfCapitalStock | 0.00 | -1.15B | -3.33B | -857.00M |
| RepaymentOfDebt | -22.00M | 0.00 | 0.00 | -140.00M |
| IssuanceOfDebt | 600.00M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 35.00M | 66.00M | 46.00M | 65.00M |
| CapitalExpenditure | -202.00M | -1.05B | -707.00M | -400.00M |
| InterestPaidSupplementalData | 10.00M | 24.00M | 39.00M | 25.00M |
| IncomeTaxPaidSupplementalData | 26.00M | 197.00M | 2.73B | 480.00M |
| EndCashPosition | 2.60B | 1.93B | 2.93B | 3.22B |
| BeginningCashPosition | 1.93B | 2.93B | 3.22B | 6.86B |
| EffectOfExchangeRateChanges | 2.00M | 0.00 | 0.00 | |
| ChangesInCash | 666.00M | -999.00M | -289.00M | -3.64B |
| FinancingCashFlow | 593.00M | 56.00M | -1.38B | -3.45B |
| CashFlowFromContinuingFinancingActivities | 593.00M | 56.00M | -1.38B | -3.45B |
| NetOtherFinancingCharges | -2.00M | -1.15B | ||
| ProceedsFromStockOptionExercised | 46.00M | 65.00M | 124.00M | |
| NetCommonStockIssuance | 35.00M | 66.00M | 46.00M | -3.26B |
| CommonStockPayments | 0.00 | -1.15B | -3.33B | -857.00M |
| CommonStockIssuance | 35.00M | 66.00M | 46.00M | 65.00M |
| NetIssuancePaymentsOfDebt | 560.00M | -10.00M | -270.00M | -184.00M |
| NetLongTermDebtIssuance | 560.00M | -10.00M | -270.00M | -184.00M |
| LongTermDebtPayments | -22.00M | 0.00 | 0.00 | -140.00M |
| LongTermDebtIssuance | 600.00M | 0.00 | 0.00 | |
| InvestingCashFlow | 1.95B | 1.95B | 4.21B | -5.18B |
| CashFlowFromContinuingInvestingActivities | 1.95B | 1.95B | 4.21B | -5.18B |
| NetOtherInvestingChanges | -23.00M | -40.00M | -30.00M | |
| NetInvestmentPurchaseAndSale | 2.15B | 3.00B | 5.00B | -4.74B |
| SaleOfInvestment | 7.92B | 9.53B | 8.78B | 6.70B |
| PurchaseOfInvestment | -5.77B | -6.53B | -3.78B | -11.44B |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -85.00M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -85.00M | 0.00 |
| NetIntangiblesPurchaseAndSale | -10.00M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -10.00M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -192.00M | -1.05B | -707.00M | -400.00M |
| PurchaseOfPPE | -192.00M | -1.05B | -707.00M | -400.00M |
| OperatingCashFlow | -1.87B | -3.00B | -3.12B | 4.98B |
| CashFlowFromContinuingOperatingActivities | -1.87B | -3.00B | -3.12B | 4.98B |
| ChangeInWorkingCapital | 233.00M | -78.00M | 689.00M | -4.01B |
| ChangeInOtherWorkingCapital | 41.00M | -439.00M | -2.06B | -4.16B |
| ChangeInOtherCurrentLiabilities | -27.00M | 106.00M | 639.00M | -754.00M |
| ChangeInOtherCurrentAssets | 38.00M | -53.00M | -605.00M | 21.00M |
| ChangeInPayablesAndAccruedExpense | -94.00M | -454.00M | -327.00M | 852.00M |
| ChangeInAccruedExpense | -2.00M | -385.00M | -340.00M | 612.00M |
| ChangeInPayable | -92.00M | -69.00M | 13.00M | 240.00M |
| ChangeInAccountPayable | -92.00M | -69.00M | 13.00M | 240.00M |
| ChangeInTaxPayable | 15.00M | -828.00M | 876.00M | |
| ChangeInIncomeTaxPayable | 15.00M | -828.00M | 876.00M | |
| ChangeInPrepaidAssets | 153.00M | 145.00M | 1.80B | -2.26B |
| ChangeInInventory | -34.00M | 83.00M | 747.00M | 492.00M |
| ChangeInReceivables | 156.00M | 534.00M | 493.00M | 1.79B |
| ChangesInAccountReceivables | 156.00M | 534.00M | 493.00M | 1.79B |
| OtherNonCashItems | 77.00M | 60.00M | 7.00M | 28.00M |
| StockBasedCompensation | 483.00M | 429.00M | 305.00M | 226.00M |
| AmortizationOfSecurities | -67.00M | -95.00M | -61.00M | 31.00M |
| DeferredTax | 828.00M | -559.00M | -318.00M | |
| DeferredIncomeTax | 828.00M | -559.00M | -318.00M | |
| DepreciationAmortizationDepletion | 215.00M | 189.00M | 621.00M | 348.00M |
| DepreciationAndAmortization | 215.00M | 189.00M | 621.00M | 348.00M |
| OperatingGainsLosses | 8.00M | 52.00M | 35.00M | |
| EarningsLossesFromEquityInvestments | 8.00M | 52.00M | 35.00M | 0.00 |
| NetIncomeFromContinuingOperations | -2.82B | -3.56B | -4.71B | 8.36B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MRNA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|